UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Therapeutic Destruction of Insulin Receptor Substrates for Cancer Treatment

Cancer research (Chicago, Ill.), 2013-07, Vol.73 (14), p.4383-4394

2013

Volltextzugriff (PDF)

S1PR3 Signaling Drives Bacterial Killing and Is Required for Survival in Bacterial Sepsis

American journal of respiratory and critical care medicine, 2017-12, Vol.196 (12), p.1559-1570

2017

Volltextzugriff (PDF)

The inhibition of IGF‐1 signaling promotes proteostasis by enhancing protein aggregation and deposition

The FASEB journal, 2016-04, Vol.30 (4), p.1656-1669

2016

Volltextzugriff (PDF)

A novel inhibitor of the insulin/IGF signaling pathway protects from age‐onset, neurodegeneration‐linked proteotoxicity

Aging cell, 2014-02, Vol.13 (1), p.165-174

2014

Volltextzugriff (PDF)

Signal Transduction by a Nondissociable Heterotrimeric Yeast G Protein

Proceedings of the National Academy of Sciences - PNAS, 2000-03, Vol.97 (7), p.3219-3223

2000

Volltextzugriff (PDF)

Abstract 5639: NT219, a novel dual inhibitor of STAT3 and IRS1/2, demonstrates anti-tumor activity with and without cetuximab in pembrolizumab-resistant head and neck cancer PDX models

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.5639-5639

2020

Volltextzugriff (PDF)

Abstract C45: NT219, a novel bispecific inhibitor of STAT3 and IRS1/2, combined with chemotherapy or MEK inhibitor in gemcitabine-resistant pancreatic tumors, induced tumor regression

Cancer research (Chicago, Ill.), 2019-12, Vol.79 (24_Supplement), p.C45-C45

2019

Volltextzugriff (PDF)

Interim safety and efficacy results from a phase 1 study of NT219 in adults with advanced solid tumors

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.3096-3096

2022

Volltextzugriff (PDF)

Sequence-based Design of Kinase Inhibitors Applicable for Therapeutics and Target Identification

The Journal of biological chemistry, 2004-01, Vol.279 (2), p.1242-1255

2004

Volltextzugriff (PDF)

Abstract B127: NT219, a novel dual inhibitor of STAT3 and IRS1/2, converts immuno-oncology resistant tumors to responders

Cancer immunology research, 2019-02, Vol.7 (2_Supplement), p.B127-B127

2019

Volltextzugriff (PDF)

Abstract 2854: Adaptation of colorectal cancer cells to the brain microenvironment: the role of IRS2

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.2854-2854

2021

Volltextzugriff (PDF)

A phase 1/2 study with open-label, dose escalation phase followed by single-arm expansion at the maximum tolerated dose to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of NT219 injection alone and in combination with cetuximab in adults with advanced solid tumors and head and neck cancer

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS3156-TPS3156

2021

Volltextzugriff (PDF)

Abstract PO-003: Adaptation of colorectal cancer cells to the brain microenvironment: The role of IRS2

Cancer research (Chicago, Ill.), 2020-12, Vol.80 (23_Supplement), p.PO-003-PO-003

2020

Volltextzugriff (PDF)

Sequence-based protein kinase inhibition: applications for drug development

BioTechniques, 2005-10, Vol.39 (4S), p.S575-S576

2005

Volltextzugriff (PDF)

Abstract 2754: NT219, a novel dual inhibitor of STAT3 and IRS1/2, converts immuno-oncology resistant tumors to responders

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.2754-2754

2018

Volltextzugriff (PDF)

Abstract 5073: NT219 induces tumor PD-L1 expression and potentiates anti-PD-1 efficacy

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.5073-5073

2023

Volltextzugriff (PDF)

Abstract B029: CM24, a novel mAb against carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1), suppresses Neutrophil Extracellular Trap (NET)-induced migration and metastasis of cancer cells

Cancer research (Chicago, Ill.), 2023-01, Vol.83 (2_Supplement_2), p.B029-B029

2023

Volltextzugriff (PDF)

The tyrphostin NT157 suppresses insulin receptor substrates and augments therapeutic response of prostate cancer

Molecular cancer therapeutics, 2014-12, Vol.13 (12), p.2827-2839

2014

Volltextzugriff (PDF)

Abstract 5181: Early activity and biomarker evaluation of NT219 in combination with cetuximab in a Phase 1/2 study of recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.5181-5181

2024

Volltextzugriff (PDF)

Abstract B117: Phase 1 study of CM24 in combination with nivolumab in patients with advanced pancreatic cancer - Survival, potential biomarker and effect on neutrophil extracellular traps (NETs)

Cancer research (Chicago, Ill.), 2024-01, Vol.84 (2_Supplement), p.B117-B117

2024

Volltextzugriff (PDF)

Abstract 4980: Rational design of combination therapies and block of acquired targeted drug resistance

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.4980-4980

2015

Volltextzugriff (PDF)

Abstract 1939: NT219, a dual inhibitor of IRS1/2 and STAT3, suppresses cancer stem cell mediated resistance to KRASG12C and KRASG12D inhibitors in solid tumors

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.1939-1939

2024

Volltextzugriff (PDF)

Abstract 266: Adaptation of colorectal cancer cells to the brain microenvironment: The role of IRS2

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.266-266

2022

Volltextzugriff (PDF)

Abstract CT136: Interim safety and efficacy results from a phase 1b study of CM24 in combination with nivolumab in adults with advanced solid tumors

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.CT136-CT136

2022

Volltextzugriff (PDF)

Abstract C005: Exploratory biomarker evaluation of the randomized Phase 2 cohort of CM24 in combination with nivolumab and chemotherapy in advanced/metastatic pancreatic cancer

Cancer research (Chicago, Ill.), 2024-09, Vol.84 (17_Supplement_2), p.C005-C005

2024

Volltextzugriff (PDF)

1 – 25 von 52

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(51)
Mit Volltextzugriff
(43)

Publikationsform

Artikel
(51)
Tagungsberichte
(1)

Sprache

Englisch
(52)

Erscheinungsjahr

n.n

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Therapeutic Destruction of Insulin Receptor Substrates for Cancer Treatment

S1PR3 Signaling Drives Bacterial Killing and Is Required for Survival in Bacterial Sepsis

The inhibition of IGF‐1 signaling promotes proteostasis by enhancing protein aggregation and deposition

A novel inhibitor of the insulin/IGF signaling pathway protects from age‐onset, neurodegeneration‐linked proteotoxicity

Signal Transduction by a Nondissociable Heterotrimeric Yeast G Protein

Abstract 5639: NT219, a novel dual inhibitor of STAT3 and IRS1/2, demonstrates anti-tumor activity with and without cetuximab in pembrolizumab-resistant head and neck cancer PDX models

Abstract C45: NT219, a novel bispecific inhibitor of STAT3 and IRS1/2, combined with chemotherapy or MEK inhibitor in gemcitabine-resistant pancreatic tumors, induced tumor regression

Interim safety and efficacy results from a phase 1 study of NT219 in adults with advanced solid tumors

Sequence-based Design of Kinase Inhibitors Applicable for Therapeutics and Target Identification

Abstract B127: NT219, a novel dual inhibitor of STAT3 and IRS1/2, converts immuno-oncology resistant tumors to responders

Abstract 2854: Adaptation of colorectal cancer cells to the brain microenvironment: the role of IRS2

Abstract PO-003: Adaptation of colorectal cancer cells to the brain microenvironment: The role of IRS2

Sequence-based protein kinase inhibition: applications for drug development

Abstract 2754: NT219, a novel dual inhibitor of STAT3 and IRS1/2, converts immuno-oncology resistant tumors to responders

Abstract 5073: NT219 induces tumor PD-L1 expression and potentiates anti-PD-1 efficacy

Abstract B029: CM24, a novel mAb against carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1), suppresses Neutrophil Extracellular Trap (NET)-induced migration and metastasis of cancer cells

The tyrphostin NT157 suppresses insulin receptor substrates and augments therapeutic response of prostate cancer

Abstract 5181: Early activity and biomarker evaluation of NT219 in combination with cetuximab in a Phase 1/2 study of recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)

Abstract B117: Phase 1 study of CM24 in combination with nivolumab in patients with advanced pancreatic cancer - Survival, potential biomarker and effect on neutrophil extracellular traps (NETs)

Abstract 4980: Rational design of combination therapies and block of acquired targeted drug resistance

Abstract 1939: NT219, a dual inhibitor of IRS1/2 and STAT3, suppresses cancer stem cell mediated resistance to KRASG12C and KRASG12D inhibitors in solid tumors

Abstract 266: Adaptation of colorectal cancer cells to the brain microenvironment: The role of IRS2

Abstract CT136: Interim safety and efficacy results from a phase 1b study of CM24 in combination with nivolumab in adults with advanced solid tumors

Abstract C005: Exploratory biomarker evaluation of the randomized Phase 2 cohort of CM24 in combination with nivolumab and chemotherapy in advanced/metastatic pancreatic cancer

Suchergebnisse filtern